The coronavirus disease 2019 (COVID19) has generated widespread healthcare concerns and has overburdened healthcare institutions. As the number of COVID19 patients recovers, so does the frequency of reports of COVID19-like symptoms following discharge. A telephone survey with standardized questions was undertaken in which participants were asked if they had had any of 25 possible sequelae after being diagnosed with COVID19 and treated with a Chlorine Dioxide Solution (CDS). One hundred sixty-one people completed the survey. We discovered that rising age is a risk factor (OR = 1.035, p = 0.028, 95% CI = 1.004-1.069), and the odds of having any symptoms in moderate patients is 0.077 compared to mild patients (P = 0.003). It was predicted that 64.6 percent of patients treated with CDS for SARS-CoV-2 infection experienced an average of 3.41 long-term effects. There were no variations in the number of sequelae reported by sex, age, COVID19 severity, or therapy method. The five most prevalent manifestations of the 25 distinct long-term symptoms observed in this study were fatigue, hair loss, dyspnea, concentration problem, and sleep difficulties. In addition, individuals treated with multiple drugs (COVID19 conventional treatment plus a CDS) had 2.7 fewer cases of sequelae, and patients treated exclusively with CDS had 6.14 fewer incidences of long-term effects. People who get a CDS are 19% less likely to experience long-term health effects than patients who receive standard COVID19 therapy. According to the findings of this study, patients who receive a CDS have a reduced probability of developing sequelae. Furthermore, the incidence of long-term effects is lower in individuals treated exclusively with a CDS. The recent findings involving Chlorine Dioxide support the development of clinical studies to evaluate its efficacy in preventing the development of COVID19 long-term effects.